SEARCH

SEARCH BY CITATION

References

  • 1
    Hui CK, Lau GK. Current issues and future directions in treatment. Semin Liver Dis 2006; 26: 192197.
  • 2
    Chen G, Lin W, Shen F, Iloeje UH, London WT. Chronic hepatitis B infection and mortality from non-liver causes: results from the Haimen cohort study. Int J Epidemiol 2005; 34: 132137.
  • 3
    Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35: 15221527.
  • 4
    Niederau C, Heintges T, Lange T, Oldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 14221427.
  • 5
    Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617624.
  • 6
    Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263270.
  • 7
    Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF, Sablon E, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37: 756763.
  • 8
    Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. HEPATOLOGY 2004; 39: 857861.
  • 9
    The EASL Jury. EASL International Consensus Conference on Hepatitis B, 13–14 September, 2002, Geneva, Switzerland: consensus statement (long version). J Hepatol 2003; 39: S3S25.
  • 10
    Lok AS, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2007; 45: 507539.
  • 11
    Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 1998; 93: 896900.
    Direct Link:
  • 12
    Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 4552.
  • 13
    Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 26822695.
  • 14
    Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. HBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123129.
  • 15
    Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with for HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 12061217.
  • 16
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 26732681.
  • 17
    Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 7382.
  • 18
    Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and Regression Trees. Monterey: Wadsworth and Brooks/Cole, 1984.
  • 19
    Steinberg D, Colla P. CART—Classification and Regression Trees. San Diego, CA: Salford Systems, 1997.
  • 20
    Korevaar A, Moucari R, Asselah T, Lada O, Boyer N, Martinot-Peignoux M, et al. High rates of HBsAg seroconversion ion chronic hepatitis B patients responding to interferon therapy: a long term follow-up study [Abstract]. HEPATOLOGY 2006: 46: 679A.
  • 21
    Colombatto P, Civitano L, Bizzarri R, Oliveri F, Choudhury S, Gieschke R, et al; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy. Antivir Ther 2006; 11: 197212
  • 22
    Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al.; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 10111020.
  • 23
    Shouval D, Akarca US, Hatzis G, Kitis G, Lai CL, Cheinquer H, et al. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (study ETV-027). J Hepatol 2006; Suppl: 45A.
  • 24
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al.; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 17431751.
  • 25
    Janssen HL, Kerhof-Los CJ, Heijtink RA, Schalm SW. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. Antiviral Res 1994; 23: 251257.
  • 26
    Keeffe EB, Dieterich DT, Han S-H, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936962.
  • 27
    Gish RG, Lau DT, Schmid P, Perrillo R. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol 2007; 102: 27182723.
    Direct Link: